

Erratum to: Antibody-mediated neutralization of myelin-associated EphrinB3 accelerates CNS remyelination

Yasir A. Syed^{1,3} · Chao Zhao¹ · Don Mahad² · Wiebke Möbius³ · Friedrich Altmann⁴ · Franziska Foss⁵ · G. A. González¹⁰ · Aycan Sentürk⁵ · Amparo Acker-Palmer⁵ · Gert Lubec^{6,9} · Kathryn Lilley⁷ · Robin J. M. Franklin¹ · Klaus-A. Nave³ · Mark R. N. Kotter^{1,3,8}

Published online: 8 May 2017
© Springer-Verlag Berlin Heidelberg 2017

Erratum to: *Acta Neuropathol* (2016) 131:281–298 DOI 10.1007/s00401-015-1521-1

The original article was published with the incorrect author group. The correct author group is provided below:

Yasir A. Syed · Chao Zhao · Don Mahad · Wiebke Möbius · Friedrich Altmann · Franziska Foss · G. A. González · Aycan Sentürk · Amparo Acker-Palmer · Gert Lubec · Kathryn Lilley · Robin J. M. Franklin · Klaus-A. Nave · Mark R. N. Kotter

The affiliation for the new author, G. A. González is as follows:

Anne McLaren Laboratory for Regenerative Medicine, and Department of Clinical Neuroscience, University of Cambridge, Cambridge, UK

It has also been noticed that Fig. 3c, d included erroneously duplicated images in the colour channels of the immunocytochemical stainings.

The correct image is given below.

The online version of the original article can be found under doi:10.1007/s00401-015-1521-1.

✉ Mark R. N. Kotter
mrk25@cam.ac.uk

- ¹ Wellcome Trust and MRC Cambridge Stem Cell Institute, Department of Clinical Neurosciences, Anne McLaren Laboratory, University of Cambridge, Cambridge CB2 0SZ, UK
- ² Centre for Neuroregeneration, Chancellor's Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK
- ³ Department of Neurogenetics, Max Planck Institute for Experimental Medicine, 37075 Goettingen, Germany
- ⁴ Department of Chemistry, University of Natural Resource and Life Sciences, Muthgasse 18, 1190 Vienna, Austria
- ⁵ Frankfurt Institute for Molecular Life Sciences and Institute of Cell Biology and Neuroscience, Goethe University Frankfurt, Max-von-Laue-Str. 9, 60438 Frankfurt am Main, Germany

- ⁶ Department of Pediatrics, Medical University Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria
- ⁷ Cambridge Centre for Proteomics, Department of Biochemistry, University of Cambridge, Tennis Court Road, Cambridge CB2 1QW, UK
- ⁸ Universitätsmedizin Göttingen, Universitätsklinik für Neurochirurgie, Robert-Koch-Straße 40, 37075 Göttingen, Germany
- ⁹ Department of Pharmaceutical Chemistry, University of Vienna, Althanstrasse 4, 1090 Vienna, Austria
- ¹⁰ Department of Clinical Neuroscience, Anne McLaren Laboratory for Regenerative Medicine, University of Cambridge, Cambridge, UK




Fig. 3 EphrinB3 activates RhoA and Pkc- α , inhibits Fak, and decreases Nkx2.2 expression. **a–d** OPCs in culture for 48 h expressed EphA4, EphB1, EphB2 and EphB3 receptor tyrosine kinases (RTKs). **e–h** EphrinB3-induced phosphorylation of EphA4 and EphB2 RTKs in OPCs [immunoprecipitation followed by WB, pTyr phosphorylated Eph-RTK, t-Eph total Eph-RTK, quantification of phosphorylated Eph-RTK relative to total Eph-RTK (ROD), $n = 3$; t test; EphA4 $***P < 0.05$; EphB1 $P > 0.1$; EphB2 $**P < 0.01$; EphB3 $P > 0.1$]. **i** Furthermore, EphrinB3-induced RhoA activity in OPCs (24-h differentiation; quantification of RhoA-GTP relative to RhoA-GDP (ROD), $n = 3$; ANOVA; $*P < 0.05$). **j–l** Whilst Marcks is localized at the membrane in differentiating OPCs cultured on control substrates, EphrinB3-mediated activation of Pkc- α resulted in phosphorylation and membrane-to-cytosol translocation of Marcks. **m** EphrinB3 also

inhibited the activation of Fak [quantification of phosphorylated (p)-Fak relative to total (t)-Fak: (ROD), $n = 3$; t test; $**P < 0.001$]. **n, o** Similar to MPE, EphrinB3 inhibited Nkx2.2 expression in OPCs (24-h differentiation, $n = 3$; ANOVA; $****P < 0.0001$; Dunnett's post hoc test PLL vs. MPE: $P < 0.001$; PLL vs. EphrinB3: $P < 0.001$; 3-day differentiation, $n = 3$; ANOVA; $****P < 0.0001$; Dunnett's post hoc test PLL vs. MPE: $P < 0.001$; PLL vs. EphrinB3: $P < 0.001$). **p** Proposed model of EphrinB3 signalling regulating OPC differentiation: the presence of EphrinB3 activates EphA4 and EphB2-RTKs. This results in activation of RhoA and Pkc- α signalling, both known to inhibit OPC differentiation. EphrinB3 also inhibits Fak signalling, a positive regulator of OPC differentiation. Failed differentiation is associated with reduced expression of Nkx2.2. Error bars \pm SEM. Scale bar in **a–d** = 40 μ m, **j–l** = 20 μ m